APA (7th ed.) Citation

A, P., M, M., L, E., A, V., S, S., AM, T., . . . M, V. (2021). Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996. American journal of hematology, 96(9), E334. https://doi.org/10.1002/ajh.26253

Chicago Style (17th ed.) Citation

A, Piciocchi, et al. "Prognostic Impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage Acute Lymphoblastic Leukemia Patients Treated in GIMEMA Clinical Trials Since 1996." American Journal of Hematology 96, no. 9 (2021): E334. https://doi.org/10.1002/ajh.26253.

MLA (9th ed.) Citation

A, Piciocchi, et al. "Prognostic Impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage Acute Lymphoblastic Leukemia Patients Treated in GIMEMA Clinical Trials Since 1996." American Journal of Hematology, vol. 96, no. 9, 2021, p. E334, https://doi.org/10.1002/ajh.26253.